SynthesisFrontiers in pharmacology2025
Cardioprotective Chinese herbs and antiretroviral drug metabolism: a systematic review of in vitro evidence.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There is considerable potential for using Chinese Herbal Medicine to manage inflammatory co-morbidities, including cardiovascular disease, in people with HIV. However, any use would require understanding herb-drug interactions with antiretroviral (ARV) drugs to ensure safety. We evaluate evidence for the effect of selected cardioprotective Chinese herbs on the activity of cytochrome P450 (CYP) enzymes that metabolise ARV drugs. Methods: We conducted a comprehensive review of six Chinese herbs commonly found in Chinese herbal formulas for treating cardiovascular conditions. We examined the effects of their extracts and reference bioactive molecules on CYP expression and enzymatic activity. The review focused on evidence from Results: 426 articles were identified of which 24 met the inclusion criteria. Overall risk of bias was low. Dan Shen and Gan Cao were the most frequently studied herbs. The most common outcome reported was no significant effect on enzyme activity, occurring in 61% of assays for Dan Shen, 37% for Gan Cao, 47% for Dang Gui, and 67% for Huang Qi. Aqueous extracts, representing the most clinically relevant preparation, of Dan Shen had minimal impact on CYP activity, while those of Gan Cao indicated potential for enzyme inhibition. In contrast, aqueous extracts of the other herbs showed a tendency toward enzyme induction. Discussion: These findings suggest that there is great potential for use of Chinese herbal medicine in managing inflammatory co-morbidities in people with HIV, but that careful consideration of herb-ARV drug interaction is warranted. While Dan Shen appears relatively safe to use in individuals receiving ARV therapy, caution is warranted for other herbs. We highlight the importance of clinically relevant extraction methods in herb-drug interaction studies. Since individual herbs may have opposing effects on ARV drug metabolism, studies conducted using whole formulae are critical.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.